Mount Sinai’s Thomas Marron, MD, PhD, discusses patient response to a vaccine that combines local low-dose radiation, intramural Flt3L, which stimulates dendritic cells, and intravenous poly-ICLC, an immune stimulating factor, with the PD-1 inhibitor pembrolizumab (KEYTRUDA®).
